Market News

FR News

20 stories
globenewswire

Planisware - Monthly information relating to the total number of shares and voting rights making-up the share capital - June 2026

Monthly information relating to the total number of shares and voting rights making-up the share capitalInformation mensuelle relative au nombre total d’actions et de droits de vote composant le capital socialArticle L. 233-8 II of the French Commercial code and article 223-16of the AMF General Reg…

GlobeNewswire en
Stocks FR
globenewswire

Technip Energies announces end of share buy-back program

Technip Energies PARIS:TE (the “Company”) announces the completion of its share buy-back program, which launch was announced in a press release dated March 18, 2026.Between March 18, 2026, and June 30, 2026, the Company acquired 4,246,851 of its own shares (representing 2.38% of the share capital…

GlobeNewswire en
Stocks FR
globenewswire

Information on share capital and voting rights - June 2026

Information on share capital and voting rightsJune 2026Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations.July 1st, 2026Statement made by:Nexans S.A.Registered office:4 Allée de l’Arche - 92400 CourbevoieRC…

GlobeNewswire en
Stocks FR
globenewswire

Weekly report TEN share buyback from June 29 to June 30, 2026

In accordance with the regulations relating to share buybacks, Technip Energies PARIS:TE declares the following purchases of its own shares from June 29, 2026, to June 30, 2026.These transactions were carried out as part of the buyback program with a discretionary mandate carried out by an investme…

GlobeNewswire en
ETFsStocks FR
globenewswire

Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary SharesPARIS, France, July 1, 2026 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris:FR0012333284 – ABVX / NASDAQ:ABVX (“Abivax” or the “Company”), a clinical-stage biotechnology company f…

GlobeNewswire en
Stocks FR